Research

Ongoing studies

A TARGETED CONGENITAL CMV SCREENING PROGRAM FOR INFANTS WITH HEARING LOSS

Congenital CMV is a common cause of neonatal hearing loss, but if identified early can be treated with medication and therapies which my improve long term outcomes. This project brings together a multidisciplinary group of health care providers across the Michigan Medicine Health system to investigate the implementation of a program that screens all infants who refer on their newborn hearing screen for congenital cytomegalovirus. Funded by the Blue Cross Blue Shield Foundation of Michigan.

CAPES: CMV & AUTISM PREVALENCE EXPLORATION STUDY

This study seeks to understand the possible connection between exposure to CMV during pregnancy and later risk of autism.

GROWING TODDLERS STUDY

The Growing Toddlers study seeks to better understand how mothers feed their toddler-aged children. Funded by the American Heart Association.

PEDIATRICIANS’ KNOWLEDGE AND PRACTICES AROUND CONGENITAL CMV

This study seeks to understand primary care pediatricians’ knowledge, beliefs, and current practices around congenital cytomegalovirus.

USING POPULATION SURVEILLANCE TECHNOLOGY FOR THE IDENTIFICATION OF INFANTS WITH CONGENITAL CYTOMEGALOVIRUS INFECTION

This project seeks to understand how we can best use the electronic medical record to identify infant risk factors for congenital cytomegalovirus, and notify providers to test infants at highest risk. We are testing the following hypotheses: 1) We hypothesize that the implementation of a Best Practice Advisory for cCMV testing will lead to increased rates of testing for cCMV during the intervention period as opposed to before the intervention (control). 2) We hypothesize that the implementation of a Best Practice Advisory for cCMV testing will lead to increased diagnosis and treatment of cCMV during the intervention period as opposed to before the intervention. 3) We hypothesize that infants identified to have cCMV through the BPA will have improved developmental outcomes at age 6 and 12 months as compared to infants diagnosed with cCMV prior to the implementation of the BPA. This hypothesis is rooted in the theory that infants will be diagnosed earlier using the BPA than those who were diagnosed prior to implementation of the BPA and will therefore have greater access to therapies and services.